UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the month of May 2023
Commission File Number 001-40316
VECTIVBIO HOLDING AG
(Exact name of registrant as specified in its charter)
Aeschenvorstadt 36
4051 Basel
Switzerland
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On May 10, 2023, VectivBio Holding AG published the invitation to its 2023 Annual General Meeting to be held on June 1, 2023. A copy of the invitation is furnished as Exhibit 99.1 hereto, and a copy of the press release announcing the publication of such invitation is furnished as Exhibit 99.2 hereto.
Exhibits | ||
99.1 | Invitation to the 2023 Annual General Meeting | |
99.2 | Press Release dated May 10, 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
VECTIVBIO HOLDING AG | ||||||
May 10, 2023 |
By: |
/s/ Claudia DAugusta | ||||
Claudia DAugusta | ||||||
Chief Financial Officer |
Exhibit 99.1
To the shareholders of VectivBio Holding AG
Invitation to the
2023 Annual General Meeting
Date and Time: Thursday, June 1, 2023, at 3:00 p.m. CEST / 9:00 a.m. EDT (doors open at 2:30 p.m. CEST / 8:30 a.m. EDT)
Location: Memox (meeting room Small Space), Elisabethenstrasse 15, 4051 Basel, Switzerland
Dear Shareholders,
We are pleased to invite you to the 2023 Annual General Meeting of VectivBio Holding AG (the Company), which will be held on Thursday, June 1, 2023, at Memox (meeting room Small Space), Elisabethenstrasse 15, 4051 Basel, Switzerland, and start at 3:00 p.m. CEST / 9:00 a.m. EDT (the 2023 Annual General Meeting).
The 2023 Annual General Meeting will be conducted in English. A record of the resolutions taken by the 2023 Annual General Meeting will be available after the 2023 Annual General Meeting on the Companys website at ir.vectivbio.com/events-and-presentations.
2022 was a very good year for VectivBio as we made significant progress against our R&D and corporate objectives, despite the challenging biotech environment. With respect to R&D activities, we advanced our pivotal program for apraglutide in patients with short bowel syndrome with intestinal failure (SBS-IF). This includes the Phase 3 STARS study, where we completed enrollment of the colon-in-continuity (CIC) cohort. We also made significant progress with the Phase 2 STARS Nutrition study, the first-ever dedicated clinical study in the subset of SBS-IF patients with CIC where we reported positive interim data. Weve also advanced our STARGAZE proof-of-concept study in acute Graft-versus-Disease (aGvHD).
Regarding our key corporate activities, last year we strengthened our financial position through a combination of two equity raises, the establishment of a loan facility and an important Japan licensing deal with Asahi Kasei Pharma. In total we gained access to up to $284 million in new funds and extended our cash runway to more than 12 months after our anticipated Phase 3 results. Looking ahead, we see tremendous momentum in 2023, with important upcoming data readouts expected throughout the year, and we continue to execute our comprehensive launch readiness plan, with the aim of realizing the full market potential of apraglutide in SBS-IF.
VectivBio is a team of industry veterans with a successful track record in rare diseases, deep scientific expertise and a relentless focus on the patient. Our purpose is to identify and develop therapeutics that are both transformational and tailored to patients needs, and we appreciate your ongoing support towards this pursuit.
Yours sincerely, |
||
|
| |
Thomas Woiwode |
Luca Santarelli | |
Chairman of the Board of Directors |
Chief Executive Officer and member of the | |
Board of Directors |
Agenda and Proposals of the Board of Directors
1. | 2022 Statutory Financial Statements and Consolidated Financial Statements; 2022 Compensation Report |
1.1 | Approval of the 2022 Statutory Financial Statements and Consolidated Financial Statements |
The Board of Directors proposes that the Statutory Financial Statements and the Consolidated Financial Statements for the financial year 2022 be approved.
Explanation by the Board of Directors
In accordance with article 698 para. 2 items 3 and 4 of the Swiss Code of Obligations (the CO) and our Articles of Association, the general meeting of shareholders (the General Meeting) is competent for approving the statutory financial statements and the consolidated financial statements. In its reports to the General Meeting, Ernst & Young, as auditors, recommends without qualification that the statutory financial statements and the consolidated financial statements of the Company be approved.
1.2 | Advisory Vote on the 2022 Compensation Report |
The Board of Directors proposes that the 2022 Compensation Report be endorsed in a non-binding advisory vote.
Explanation by the Board of Directors
In line with best practice, the Board of Directors submits the 2022 Compensation Report to an advisory vote of the General Meeting.
The Compensation Report as filed with the U.S. Securities Exchange Commission as Exhibit 99.2 to the Companys Form 6-K on April 19, 2023 can be downloaded from the Companys website: ir.vectivbio.com/financial-information/sec-filings.
It explains the governance framework and the principles underlying the compensation system at the Company. In addition, the Compensation Report sets out the remuneration of the Board of Directors and the Executive Committee paid or granted in respect of 2022 as required under the Swiss Ordinance against Excessive Compensation of Listed Companies.
2. | Appropriation of 2022 Financial Results |
The Board of Directors proposes that the loss of the Company be carried forward as follows:
Loss carried forward from the financial year 2021 |
CHF | -28,435,076 | ||||||
Loss for the financial year 2022 |
CHF | -36,211,404 | ||||||
|
|
|||||||
Loss to be carried forward |
CHF | -64,646,480 |
Explanation by the Board of Directors
In accordance with article 698 para. 2 item 4 CO and our Articles of Association, the General Meeting is competent for passing resolutions on the appropriation of the financial result.
3. | Discharge of the Board of Directors and of the Executive Committee |
The Board of Directors proposes that all members of the Board of Directors and of the Executive Committee be discharged from liability for their activities during the financial year 2022.
Explanation by the Board of Directors
In accordance with article 698 para. 2 item 7 CO and our Articles of Association, the General Meeting is competent for granting discharge to the members of the Board of Directors and the persons entrusted with management.
4. | Re-election of the Chairman and the Other Members of the Board of Directors |
The term of office of the Chairman and all members of the Board of Directors expires upon completion of the 2023 Annual General Meeting. The Board of Directors proposes that all current members of the Board of Directors, including the Chairman, be re-elected for a term of office until completion of the 2024 Annual General Meeting.
Explanation by the Board of Directors
Pursuant to article 698 para. 2 item 2 and para. 3 item 1 CO and our Articles of Association, the General Meeting is competent for the re-election of the members of the Board of Directors and its Chairman. The elections will be held on an individual basis.
Information on the professional background of the Chairman and the other members of the Board of Directors can be found in the 2022 Annual Report and at vectivbio.com/about-us/#board-of-directors.
4.1 | Re-election of Thomas Woiwode (as Chairman and member of the Board of Directors) |
4.2 | Re-election of Sandip Kapadia |
4.3 | Re-election of Paul Rutherford Carter |
4.4 | Re-election of Luca Santarelli |
4.5 | Re-election of Hans Schikan |
4.6 | Re-election of Murray Willis Stewart |
4.7 | Re-election of Wouter Joustra |
5. | Re-election of the Members of the Compensation Committee |
The term of office of the members of the Compensation Committee expires upon completion of the 2023 Annual General Meeting. The Board of Directors proposes that all current members of the Compensation Committee be re-elected for a term of office until completion of the 2024 Annual General Meeting, subject to their re-election as members of the Board of Directors under agenda item 4.
Explanation by the Board of Directors
Pursuant to article 698 para. 3 item 2 CO and our Articles of Association, the General Meeting is competent for the re-election of the members of the Compensation Committee. The elections will be held on an individual basis. The Board of Directors intends to re-appoint Paul Rutherford Carter, if re-elected, as Chairman of the Compensation Committee.
5.1 | Re-election of Paul Rutherford Carter |
5.2 | Re-election of Murray Willis Stewart |
5.3 | Re-election of Thomas Woiwode |
6. | Re-election of the Statutory Auditors |
The Board of Directors proposes that Ernst & Young AG, in Basel, Switzerland, be re-elected as the Companys statutory auditors for the financial year 2023.
Explanation by the Board of Directors
Pursuant to article 698 para. 2 item 2 CO and our Articles of Association, the General Meeting is competent for the re-election of the auditors. Ernst & Young confirmed its independence required for this mandate.
7. | Re-election of the Independent Proxy |
The Board of Directors proposes that Buis Bürgi AG, Zurich, Switzerland, be re-elected as independent proxy for a term of office until completion of the 2024 Annual General Meeting.
Explanation by the Board of Directors
Pursuant to article 698 para. 3 item 3 CO and our Articles of Association, the General Meeting is competent for the re-election of the independent proxy. Buis Bürgi AG confirmed its independence required for this mandate.
8. | Compensation of the Board of Directors and the Executive Committee |
8.1 | Approval of the Maximum Aggregate Amount of Compensation of the Board of Directors |
The Board of Directors proposes that a maximum aggregate amount of compensation of the Board of Directors for the period from the 2023 Annual General Meeting to the 2024 Annual General Meeting of CHF 2,200,000 be approved.
Explanation by the Board of Directors
Pursuant to article 698 para. 3 item 4 CO and our Articles of Association, the General Meeting is competent for the approval of the maximum aggregate amount of compensation of the Board of Directors for the upcoming term of office.
The compensation of the members of the Board of Directors and its committees is comprised of cash board and committee fees and annual equity grants under the Companys 2021 Equity Incentive Plan. Additional information on the compensation system for the Board of Directors can be found in the 2022 Compensation Report.
The proposed maximum aggregate amount comprises the cash board and committee fees and the fair value at grant of the annual equity grants in respect of the period from the 2023 Annual General Meeting to the 2024 Annual General Meeting for the members of the Board of Directors proposed for re-election under agenda item 4 other than Luca Santarelli, who does not receive any compensation in relation to his position as a member of the Board of Directors. Due to changes in the composition of the Board of Directors since the 2022 Annual General Meeting, the proposed maximum aggregate amount has been increased in line with the compensation recommendations by the Companys compensation advisor to attract, retain and motivate qualified directors in a highly competitive environment and also takes into account potential compensation increases due to general inflation. The proposed maximum aggregate amount excludes any legally required employer contributions to social security systems. Some compensation elements are expected to be paid in USD. The USD : CHF exchange rate used for calculating the maximum aggregate amount is 1 : 0.91. The proposed maximum aggregate amount excludes any currency exchange rate fluctuation until final payment of all compensation elements.
The actual payout, including the distribution among these non-binding components, for the upcoming term of office will be disclosed in the 2023 and 2024 Compensation Reports, respectively.
8.2 | Approval of the Maximum Aggregate Amount of Compensation of the Executive Committee |
The Board of Directors proposes that a maximum aggregate amount of compensation of the Executive Committee for the financial year 2024 of CHF 18,500,000 be approved.
Explanation by the Board of Directors
Pursuant to article 698 para. 3 item 4 CO and our Articles of Association, the General Meeting is competent for the approval of the maximum aggregate amount of compensation of the Executive Committee for the following financial year.
The compensation of the members of the Executive Committee is comprised of an annual base salary, an annual cash bonus and an annual equity grant under the Companys 2021 Equity Incentive Plan as well as benefits and pension contributions. Additional information on the compensation system for the Executive Committee can be found in the 2022 Compensation Report.
The proposed maximum aggregate amount comprises the annual base salaries, the annual cash bonuses (assuming the maximum possible payout, i.e. 200% of target, if all performance targets are exceeded) and the fair value at grant of the annual equity grants as well as the benefits and pension contributions to be paid (or expected to be paid) by the Company in respect of the financial year 2024. The proposed maximum aggregate amount is calculated based on eight members of the Executive Committee. The increase in the proposed maximum aggregate amount compared with the amount for the financial year 2023 reflects the expected expansion of the Executive Committee from seven to eight members in 2024 and also takes into account potential compensation increases due to general inflation. Further, the Board is of the view that the proposed maximum aggregate amount is necessary to attract, retain and motivate qualified executive officers in a highly competitive environment The proposed maximum aggregate amount excludes any legally required employer contributions to social security systems. Some compensation elements are expected to be paid in USD. The USD : CHF exchange rate used for calculating the maximum aggregate amount is 1 : 0.91. The proposed maximum aggregate amount excludes any currency exchange rate fluctuation until final payment of all compensation elements.
The actual payout, including the distribution among these non-binding components, for the financial year 2024 will be disclosed in the 2024 Compensation Report.
9. | Introduction of a Capital Range |
The Board of Directors proposes to cancel the existing authorized share capital pursuant to article 3a of the Articles of Association and to replace it with a capital range ranging from CHF 3,369,589.50 (lower limit) to CHF 5,054,384.25 (upper limit) as follows (for ease of comparison, the redline below shows the changes of the new capital range compared with the current authorized share capital):
Kapitalband |
1 Die Gesellschaft verfügt über ein Kapitalband zwischen CHF 3369589.50 (untere Grenze) und CHF 5054384.25 (obere Grenze). Der Verwaltungsrat ist im Rahmen des Kapitalbands ermächtigt, jederzeit, |
Range |
1 The Company has a capital range ranging from CHF 3,369,589.50 (lower limit) to CHF 5,054,384.25 (upper limit). The Board of Directors shall be authorized within the capital range to increase the share |
einschliesslich im Zusammenhang mit einer beabsichtigten Übernahme, bis zum |
capital at any time, including in connection with an intended takeover, until June | |||||
2 Zeichnung und Erwerb der neuen Aktien sowie jede nachfolgende Übertragung der Aktien unterliegen den Beschränkungen von Artikel 5 dieser Statuten. | 2 The subscription and acquisition of the new shares as well as any subsequent transfer of the shares shall be subject to the restrictions pursuant to Article 5 of these articles of association. | |||||
3 Der Verwaltungsrat legt den Ausgabebetrag, die Art der Einlagen (einschliesslich durch Umwandlung von frei verwendbarem Eigenkapital, durch Sacheinlage oder durch Verrechnung), den Zeitpunkt der Ausgabe, die Bedingungen der Bezugsrechtsausübung und den Beginn der Dividendenberechtigung fest. Dabei kann der Verwaltungsrat neue Aktien mittels Festübernahme durch eine Bank, ein Bankenkonsortium oder einen anderen Dritten und anschliessendem Angebot an die bisherigen Aktionäre oder an Dritte (sofern die Bezugsrechte der bisherigen Aktionäre aufgehoben sind oder nicht gültig ausgeübt werden) ausgeben. Der Verwaltungsrat ist ermächtigt, den Handel mit Bezugsrechten zu ermöglichen, zu beschränken oder auszuschliessen. Nicht ausgeübte Bezugsrechte kann der Verwaltungsrat verfallen lassen, oder er kann diese bzw. Aktien, für welche Bezugsrechte eingeräumt, aber nicht ausgeübt werden, zu Marktkonditionen platzieren oder anderweitig im Interesse der Gesellschaft verwenden. | 3 The Board of Directors shall determine the issue price, the type of contribution (including by conversion of freely disposable equity, by a contribution in kind or by way of set-off), the date of issue, the conditions for the exercise of pre-emptive rights and the beginning date for dividend entitlement. In this regard, the Board of Directors may issue new shares by means of a firm underwriting through a financial institution, a syndicate of financial institutions or another third party and a subsequent offering of these shares to the existing shareholders or third parties (if the pre-emptive rights of the existing shareholders have been withdrawn or have not been duly exercised). The Board of Directors is entitled to permit, to restrict or to exclude the trading in pre-emptive rights. It may permit the expiration of pre-emptive rights that have not been exercised, or it may place such rights or shares as to which pre-emptive rights have been granted, but not exercised, at market conditions or may use them otherwise in the interest of the Company. |
4 Der Verwaltungsrat ist ferner ermächtigt, das Bezugsrecht der bisherigen Aktionäre aufzuheben oder zu beschränken und Dritten, der Gesellschaft oder einer ihrer Konzerngesellschaften zuzuweisen: | 4 The Board of Directors is further authorized to withdraw or limit the pre-emptive rights of the existing shareholders and allocate such rights to third parties, the Company or any of its group companies: | |||||
(a) wenn der Ausgabebetrag der neuen Aktien unter Berücksichtigung des Marktpreises festgesetzt wird; oder | (a) if the issue price of the new shares is determined by reference to the market price; or | |||||
(b) für die Beschaffung von Kapital auf eine schnelle und flexible Weise, welche ohne den Ausschluss der Bezugsrechte der bisherigen Aktionäre nicht oder nur schwer, mit Verzögerungen oder zu wesentlich schlechteren Bedingungen möglich wäre; oder | (b) for raising capital in a fast and flexible manner, which would not be possible, or might only be possible with great difficulty or delays or at significantly less favorable conditions, without the exclusion of the pre-emptive rights of the existing shareholders; or | |||||
(c) für die Übernahme von Unternehmen, Unternehmensteilen oder Beteiligungen, den Erwerb von Produkten, Immaterialgütern oder Lizenzen durch oder Investitionsvorhaben der Gesellschaft oder einer ihrer Konzerngesellschaften oder für die Finanzierung oder Refinanzierung solcher Transaktionen durch eine Aktienplatzierung; oder | (c) for the acquisition of companies, part(s) of companies or participations, for the acquisition of products, intellectual property or licenses by or for investment projects of the Company or any of its group companies, or for the financing or refinancing of any of such transactions through a placement of shares; or | |||||
(d) zum Zwecke der Erweiterung des Aktionärskreises der Gesellschaft in bestimmten geographischen, Finanz- oder Investoren-Märkten, zur Beteiligung von strategischen Partnern oder im Zusammenhang mit der Kotierung von neuen Aktien an inländischen oder ausländischen Börsen; oder | (d) for purposes of broadening the shareholder constituency of the Company in certain geographic, financial or investor markets, for purposes of the participation of strategic partners, or in connection with the listing of new shares on domestic or foreign stock exchanges; or | |||||
(e) für die Einräumung einer Mehrzuteilungsoption (Greenshoe) oder einer Option zur Zeichnung von zusätzlichen Aktien an die betreffenden Erstkäufer oder Festübernehmer im Rahmen einer Aktienplatzierung oder eines Aktienverkaufs; oder | (e) for purposes of granting an over-allotment option (Greenshoe) or an option to subscribe for additional shares in a placement or sale of shares to the respective initial purchaser(s) or underwriter(s); or | |||||
(f) für die Beteiligung von Mitgliedern des Verwaltungsrates, Mitgliedern der Geschäftsleitung, Arbeitnehmern, Beauftragten, Beratern oder anderen Personen, die für die Gesellschaft oder eine ihrer Konzerngesellschaften Leistungen erbringen; oder | (f) for the participation of members of the Board of Directors, members of the Executive Committee, employees, contractors, consultants or other persons performing services for the benefit of the Company or any of its group companies; or |
(g) wenn ein Aktionär oder eine Gruppe von in gemeinsamer Absprache handelnden Aktionären mehr als 18% des im Handelsregister eingetragenen Aktienkapitals der Gesellschaft auf sich vereinigt hat, ohne allen übrigen Aktionären ein vom Verwaltungsrat empfohlenes Übernahmeangebot unterbreitet zu haben; oder | (g) following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 18% of the share capital registered in the commercial register without having submitted to all other shareholders a takeover offer recommended by the Board of Directors; or | |||||
(h) zur Abwehr eines unterbreiteten, angedrohten oder potentiellen Übernahmeangebotes, welches der Verwaltungsrat, nach Konsultation mit einem von ihm beigezogenen unabhängigen Finanzberater, den Aktionären nicht zur Annahme empfohlen hat bzw. nicht empfehlen wird, weil der Verwaltungsrat das Übernahmeangebot in finanzieller Hinsicht gegenüber den Aktionären nicht als fair oder nicht als im Interesse der Gesellschaft liegend beurteilt. | (h) for the defense of an actual, threatened or potential takeover offer that the Board of Directors, upon consultation with an independent financial adviser retained by it, has not recommended or will not recommend to the shareholders to accept on the basis that the Board of Directors does not find such takeover offer to be financially fair to the shareholders or to be in the Companys interest. |
Explanation by the Board of Directors
Under the new Swiss corporate law, which entered into force on January 1, 2023, the previously available authorized share capital has been replaced with the so-called capital range. As the former authorized share capital, the proposed capital range gives the Company the necessary flexibility to raise capital on the financial markets without having to convene another General Meeting, in order to support the Companys growth plan and to be able to fund the Companys research and clinical development programs and other strategic projects. Further information on the new Swiss corporate law can be found in section 1.1 of the annex to this invitation to the 2023 Annual General Meeting.
The proposed introduction of a capital range is subject to a qualified majority of two thirds of the votes of the shares represented at the General Meeting.
10. Increase of the Conditional Share Capital for Participation Programs
The Board of Directors proposes (i) that the Companys conditional share capital for participation programs be increased by CHF 692,576.75 to the maximum amount of CHF 1,233,908.75, allowing the issuance of up to 24,678,175 registered shares with a par value of CHF 0.05 each, and, accordingly, to amend article 3b (Conditional Share Capital for Participation Programs), paragraph 1, of the Articles of Association and (ii) to introduce a new paragraph 4 to article 3b of the Articles of Association as follows (amendments are underlined):
1 Das Aktienkapital kann sich durch Ausgabe von höchstens 24678175 voll zu liberierenden Namenaktien im Nennwert von je CHF 0.05 um höchstens CHF 1233908.75 erhöhen durch Ausgabe von Rechten auf den Bezug neuer Aktien im Sinne von Artikel 653 Abs. 1 OR an Mitglieder des Verwaltungsrates, Mitglieder der Geschäftsleitung oder Arbeitnehmer, Beauftragte oder Berater der Gesellschaft und ihrer Konzerngesellschaften oder andere Personen, welche Dienstleistungen für die Gesellschaft oder ihre Konzerngesellschaften erbringen. | 1 The share capital may be increased in an amount not to exceed CHF 1,233,908.75 through the issuance of up to 24,678,175 fully paid in registered shares with a par value of CHF 0.05 per share through the issuance of rights to subscribe for new shares within the meaning of article 653(1) CO to members of the Board of Directors, members of the Executive Committee or employees, contractors or consultants of the Company or its group companies, or other persons providing services to the Company or its group companies. | |
4 Die Erklärung über den Erwerb von Aktien gestützt auf diesen Artikel 3b hat auf diesen Artikel 3b hinzuweisen und in einer Form, die den Nachweis durch Text ermöglicht, zu erfolgen. Ein Verzicht auf ein Recht auf Erwerb von Aktien gestützt auf diesen Artikel 3b kann auch formlos oder durch Zeitablauf erfolgen; das gilt auch für den Verzicht auf die Ausübung und den Verfall dieses Rechts. | 4 The declaration of acquisition of the shares based on this Article 3b shall refer to this Article 3b and be made in a form that allows proof by text. A waiver of the right to acquire shares based on this Article 3b may also occur informally or by lapse of time; this also applies to the waiver of the exercise and forfeiture of this right. |
Paragraphs 2 and 3 of article 3b of the Articles of Association remain unchanged.
Explanation by the Board of Directors
The increase of the conditional share capital for participation programs will allow future equity grants to employees, directors and consultants to cover the projected mid-term needs. While in order to limit dilution of shareholders, the Company aims to net settle any exercised options or to use shares purchased on the market therefor, from an accounting perspective, it is important for the Company that all options that are outstanding or will be granted in the mid-term are fully covered by conditional share capital. The proposed addition of para. 4 addresses a new requirement under the revised Swiss corporate law.
This proposed amendment is subject to a qualified majority of two thirds of the votes of the shares represented at the General Meeting.
11. Amendments to the Articles of Association
Explanation by the Board of Directors
On June 19, 2020, the Swiss Parliament adopted a revision of the Swiss corporate law, which entered into force on January 1, 2023, subject to certain transitional provisions. Pursuant to the new corporate law, Swiss corporations are obliged to revise their corporate documents to comply with the new corporate law by the end of 2024.
The proposed amendments to our Articles of Association and the explanations thereto can be found in the annex to this invitation to the 2023 Annual General Meeting.
11.1 | Share Certificates and Intermediated Securities, Share Register, Restrictions on Registration, Nominees |
The Board of Directors proposes to amend articles 4 and 5 of the Articles of Association according to section 2.1 of the annex to this invitation to the 2023 Annual General Meeting.
11.2 | Shareholder Rights, General Meeting of Shareholders, Notices and Communications |
The Board of Directors proposes to amend articles 7, 8, 9, 10, 13, 24 and 34 of the Articles of Association according to section 2.2 of the annex to this invitation to the 2023 Annual General Meeting.
11.3 | Board of Directors, Compensation of the Executive Committee, Mandates Outside the Company |
The Board of Directors proposes to amend articles 18, 19, 26, 27 and 29 of the Articles of Association according to section 2.3 of the annex to this invitation to the 2023 Annual General Meeting.
11.4 | Jurisdiction Clause |
The Board of Directors proposes to introduce a new article 35 to the Articles of Association according to section 2.4 of the annex to this invitation to the 2023 Annual General Meeting.
Organizational Information
1. | Admission to the 2023 Annual General Meeting |
Shareholders entered in the Companys share register with the right to vote as per the Record Date (as defined below) will be entitled to participate in the 2023 Annual General Meeting. Shareholders wishing to attend the 2023 Annual General Meeting in person must present proof of ownership and appropriate identification at the General Meeting. Shareholders registered as shareholders with voting rights in the share register on the Record Date (Holders of Record) intending to participate and vote their shares in person at the 2023 Annual General Meeting must check the appropriate box and download their admission ticket on the Computershare portal using their access information provided in the Notice (as defined below). Shareholders holding their shares on the Record Date through their broker or bank (Street Name Holders) who wish to attend and vote their shares in person at the 2023 Annual General Meeting must obtain a valid legal proxy from their bank or broker following their instructions.
Please note that shareholders do not need to attend the 2023 Annual General Meeting in person to cast their vote and that they may be represented by (i) the independent proxy, Buis Bürgi AG, Mühlebachstrasse 8, 8008 Zurich, Switzerland (see 4. Instructions below) or (ii) their proxy, who does not need to be a shareholder, by completing and signing a proxy form. Such proxy form can be downloaded on the Computershare portal alongside the admission ticket. The proxy must present an original of the signed proxy form at the General Meeting together with the admission ticket, proof of ownership and appropriate identification.
2. | Eligibility to Vote |
Shareholders registered as shareholders with voting rights in the share register of the Company maintained by our share registrar and transfer agent, Computershare Trust Company N.A. (Computershare), as of May 2, 2023, at 10:00 p.m. CEST / 4:00 p.m. EDT (the Record Date), will be entitled to vote at the 2023 Annual General Meeting. Shareholders who sell their shares prior to the 2023 Annual General Meeting will not be able to vote those shares at the 2023 Annual General Meeting. Shareholders who purchase shares between the Record Date and the completion of the 2023 Annual General Meeting will not be able to vote those shares at the 2023 Annual General Meeting.
Our Articles of Association provide that no person or entity shall be registered in our share register as a shareholder with voting rights for, and no person or entity may directly or indirectly, formally, constructively or beneficially own, or otherwise control or direct, alone or together with third parties, voting rights (whether exercisable or not) with respect to, more than 18% of the share capital registered in the commercial register. This restriction shall also apply to persons or entities who hold or acquire some or all of their shares through nominees. If shares are being held by a nominee for third-party beneficiaries that control (alone or
together with other parties) voting rights with respect to more than 18% of the share capital recorded in the commercial register, the Board of Directors may cancel the registration of the shares with voting rights held by such nominee in excess of the 18% limit. Shareholders who had been registered with, and / or had been allocated, directly or through a nominee, more than 18% of the share capital registered in the commercial register prior to our initial public offering remained or were registered with voting rights for such shares.
No shareholder may exercise, directly or indirectly, voting rights with respect to own or represented shares in excess of 18% of the share capital registered in the commercial register. Legal entities and partnerships or other groups of persons or joint owners who are interrelated to one another through capital ownership, voting rights, uniform management or are otherwise linked as well as individuals or legal entities and partnerships who act in concert or otherwise act in a coordinated manner shall be treated as one single person. This voting rights limitation shall not apply to the exercise of voting rights by shareholders or their proxies to the extent that their shares are validly registered with voting rights in the share register pursuant to our Articles of Association and they are still in compliance with these provisions. Any shareholder who returns a proxy card or votes electronically thereby confirms that is does not exceed the aforementioned 18% thresholds, to the extent such thresholds apply to it.
These restrictions on registration or voting do not impact the trading of shares before, during or after the 2023 Annual General Meeting.
3. | Annual General Meeting Notice and Voting Materials |
Holders of Record will receive the 2023 Annual General Meeting notice (the Notice) directly from Computershare. The Notice will contain access information for the Computershare portal, by which Holders of Record may give voting instructions and authorization to the independent proxy electronically, as well as information on voting by mail.
Street Name Holders are unknown to the Company or Computershare. Street Name Holders should be able to vote on the portal designated by their broker or bank. Street Name Holders will only be able to give voting instructions and authorizations to the independent proxy via the portal designated by their broker or bank and should therefore contact their broker or bank or its designated agent about how to do so.
Shareholders may order a copy of this invitation to the 2023 Annual General Meeting and a proxy card as indicated in the Notice. This invitation to the 2023 Annual General Meeting can also be accessed at www.edocumentview.com/VECT.
4. | Voting Instructions |
Voting rights can be exercised through a proxy, who does not need to be a shareholder, or the independent proxy, Buis Bürgi AG, Mühlebachstrasse 8, 8008 Zurich, Switzerland. Shareholders may give a proxy and voting instructions to the independent proxy via Computershare or, if applicable, the portal designated by their broker or bank, prior to the 2023 Annual General Meeting.
The independent proxy will be present at the 2023 Annual General Meeting in order to vote on behalf of the shareholders from whom Computershare has received a valid proxy and voting instructions. Holders of Record who have timely submitted their proxy but have not specifically indicated how to vote their shares instruct the independent proxy to vote in accordance with the recommendations of the Companys Board of Directors with regard to the agenda items and proposals listed in this invitation to the 2023 Annual General Meeting. If any modifications to the agenda items or the proposals identified in this invitation to the 2023 Annual General Meeting, or other matters on which voting is permissible under Swiss law, are properly presented at the 2023 Annual General Meeting for consideration, the Holders of Record and the Street Name Holders instruct the independent proxy, in the absence of other specific instructions, to vote in accordance with the recommendations of the Companys Board of Directors.
Voting Instructions by Holders of Record
The Company recommends that Holders of Record give a proxy and voting instructions to the independent proxy electronically through the Computershare portal with the individual shareholder control number (QR Code). To do so, Holders of Record should follow the instructions given in the Notice.
Holders of Record may also give a proxy and voting instructions to the independent proxy through Computershare by mail, using the proxy card. Holders of Record may order a copy of this invitation to the 2023 Annual General Meeting and a proxy card as indicated in the Notice. Holders of Record should send their completed and signed proxy card to Computershare at one of the following addresses:
By Mail: | By Overnight Delivery: | |
Computershare Investor Services | Computershare Investor Services | |
P.O. Box 43078 | 150 Royall St., Suite 101 | |
Providence, RI 02940-3078 | Canton, MA 02021 | |
United States of America | United States of America |
Electronic voting instructions and proxy cards must be received by Computershare no later than May 31, 2023, at 5:59 a.m. CEST / May 30, 2023, at 11:59 p.m. EDT. Shareholders who voted electronically or by mail in advance are not permitted to cast their votes at the 2023 Annual General Meeting in person, but can attend the 2023 Annual General Meeting as guests. Should Computershare receive voting instructions from the same shareholder both electronically and by mail, the instructions last received will be taken into account.
Voting Instructions by Street Name Holders
Street Name Holders who would like to give voting instructions should follow the instructions of their broker or bank or its designated agent and should use the portal designated by their broker or bank.
Street Name Holders should observe the deadlines to submit voting instructions that are set in the instructions of their broker or bank or its designated agent.
5. | Record of Resolutions |
A record of the resolutions taken by the 2023 Annual General Meeting will be available after the 2023 Annual General Meeting on the Companys website at ir.vectivbio.com/events-and-presentations.
6. | Annual Report |
The Annual Report for the financial year 2022 on Form 20-F (including the 2022 Consolidated Financial Statements and the corresponding report of the Auditors), the 2022 Statutory Financial Statements, the 2022 Compensation Report and the corresponding reports of the Auditors published on Form 6-K on April 19, 2023 are available electronically on the Companys website at https://ir.vectivbio.com/financial-information/sec-filings.
Contact Address
VectivBio Holding AG
Aeschenvorstadt 36
4051 Basel
Switzerland
Investor Relations:
Patrick Malloy
+41 61 551 30 36
ir@vectivbio.com
http://www.vectivbio.com
Basel, May 10, 2023 |
VectivBio Holding AG |
For the Board of Directors |
![]() |
Thomas Woiwode |
Chairman of the Board of Directors |
Annex Proposed Amendments to the Articles of Association (Agenda Item 11)
1. | Overview |
1.1 | Introductory Remarks |
On June 19, 2020, the Swiss Parliament adopted a revision of the Swiss corporate law (Corporate Law Reform), which entered into force on January 1, 2023, subject to certain transitional provisions. The Corporate Law Reform primarily aims at modernizing Swiss corporate law, strengthening shareholder rights and integrating the provisions of the Ordinance against Excessive Compensation in Listed Companies, which entered into force on January 1, 2014, in the Swiss Code of Obligations.
The new Swiss corporate law provides for a transitional period of two years during which corporations have to amend their Articles of Association and other regulations to reflect the changes in the law. Accordingly, the Board of Directors proposes to the shareholders to revise the Articles of Association at this General Meeting.
The proposed amendments to the Articles of Association are grouped by thematic categories and submitted to the General Meeting for approval under four separate agenda items. References in this overview are to the proposed revised Articles of Association. In case of discrepancies between the English and the German version of the Articles of Association, the German version shall prevail.
1.2 | Share Certificates and Intermediated Securities, Share Register, Restrictions on Registration, Nominees |
The proposed amendments to the Articles of Association are clarifications resulting from recent case law (article 4 para. 2) or prevailing practice (article 5 para. 1).
1.3 | Shareholder Rights, General Meeting of Shareholders, Notices and Communications |
The Corporate Law Reform expands the powers of the General Meeting. The Board of Directors proposes to update article 7 of the Articles of Association accordingly.
The revised corporate law further strengthens the rights of shareholders by lowering the threshold for the right to request an Extraordinary General Meeting from 10% to 5% of the share capital or votes. The Board of Directors proposes to reflect this change in article 8 para. 2 lit. c of the Articles of Association.
The proposed changes to articles 9 and 10 of the Articles of Association reflect the new corporate law and new possible forms of communication (article 9 para. 3), new requirements in connection with the invitation to a General Meeting (article 9 para. 4) and the new thresholds for the right to request that an item be included in the agenda of a General Meeting or that a proposal relating to an agenda item be included in the invitation to the General Meeting (article 10 para. 1).
The proposed changes to articles 13 and 24 of the Articles of Association reflect the new corporate law.
The revised law allows corporations to communicate also through electronic means. Accordingly, the Board of Directors proposes to revise article 34 of the Articles of Association to allow the Company to make use of the new flexibility when appropriate, in particular with regard to the use of electronic means.
1.4 | Board of Directors, Compensation of the Executive Committee, Mandates Outside the Company |
The proposed changes to articles 18, 19, 26, 27 and 29 of the Articles of Association reflect the new corporate law.
1.5 | Jurisdiction Clause |
The proposed introduction of a new article 35 to our Articles of Association is aimed at improving the legal certainty regarding the place of jurisdiction for any disputes arising out of or in connection with the corporate relationship, in particular in an international context. Further, the jurisdiction clause reflects the applicable rules under Swiss law (including the Swiss Federal Act on Private International Law) and the Lugano Convention and is also in line with the practice of other listed Swiss companies.
2. | Proposed Revised Provisions of the Articles of Association |
2.1 | Agenda Item 11.1: Share Certificates and Intermediated Securities, Share Register, Restrictions on Registration, Nominees |
The Board of Directors proposes to amend articles 4 and 5 of the Articles of Association as shown below:
Artikel 4
(Absatz 1 unverändert)
2 Ein Aktionär hat keinen Anspruch auf Umwandlung von in bestimmter Form ausgegebenen Namenaktien in eine andere Form. Insbesondere hat der Aktionär keinen Anspruch auf die Verbriefung der Mitgliedschaft in einem Wertpapier. Jeder Aktionär kann jedoch von der Gesellschaft jederzeit die Ausstellung einer Bescheinigung über die von ihm gemäss Aktienbuch gehaltenen Namenaktien verlangen. |
Article 4
(Paragraph 1 unchanged)
2 A shareholder has no right to request a conversion of the registered shares issued in one form into another form. In particular, no shareholder has a right to request that its membership be certified in a security certificate. Each shareholder may, however, at any time request from the Company a written confirmation of the registered shares held by such shareholder, as reflected in the share register. |
(Absatz 3 unverändert)
Artikel 5
1 Die Gesellschaft oder ein von ihr beauftragter Dritter führt für die Namenaktien ein
Aktienbuch, in welches die Eigentümer und Nutzniesser mit Name und Vorname (bei juristischen Personen die Firma), Adresse und Staatsangehörigkeit (bei juristischen Personen der Sitz) eingetragen werden. Wechselt eine im Aktienbuch
eingetragene Person ihre Kontaktdaten |
(Paragraph 3 unchanged)
Article 5
1 The Company shall maintain, itself or through a third party, a share register for the registered shares
that lists the surname and name (the name of the company in case of a legal entity), the address and the nationality (the registered office in case of a legal entity) of the shareholders or usufructuaries. A person registered in the share register
shall notify the share registrar of any change in contact information | |
(Übrige Absätze unverändert) | (Remaining paragraphs unchanged) |
2.2 | Agenda Item 11.2: Shareholder Rights, General Meeting of Shareholders, Notices and Communications |
The Board of Directors proposes to amend articles 7, 8, 9, 10, 13, 24 and 34 of the Articles of Association as shown below:
Artikel 7
(Absatz 1 unverändert) |
Article 7
(Paragraph 1 unchanged) | |
2 Der Generalversammlung stehen folgende unübertragbaren Befugnisse zu: | 2 The General Meeting of Shareholders shall have the following inalienable powers: | |
(Ziffern 1 bis 5 unverändert) | (Items 1 to 5 unchanged) | |
6. die Genehmigung der Jahresrechnung sowie die Beschlussfassung über die Verwendung des Bilanzgewinnes, insbesondere die Festsetzung der (Zwischen-)Dividende (und die Genehmigung des dafür erforderlichen Zwischenabschlusses), und die Rückzahlung der gesetzlichen Kapitalreserve; | 6. the approval of the annual financial statements as well as the resolution on the allocation of profit shown on the balance sheet, in particular the determination of (interim) dividends (and the approval of the interim financial statements required for this purpose), and the repayment of the statutory capital reserves; | |
(Ziffer 7 unverändert) | (Item 7 unchanged) | |
8. die Dekotierung der Beteiligungspapiere der Gesellschaft; | 8. the delisting of the Companys equity securities; | |
9. sofern erforderlich, die Genehmigung des Berichts über nichtfinanzielle Belange nach Artikel 964c OR; | 9. if required, the approval of the report on non-financial matters pursuant to article 964c CO; | |
(Bisherige Ziffern 8 und 9 entsprechend neu nummeriert) | (Existing items 8 and 9 renumbered accordingly) |
Artikel 8 | Article 8 | |
(Absatz 1 unverändert) | (Paragraph 1 unchanged) | |
2 Ausserordentliche Generalversammlungen finden statt, sofern | 2 Extraordinary General Meetings of Shareholders shall be held if | |
(Buchstaben (a) und (b) unverändert) | (Letters (a) and (b) unchanged) | |
(c) Aktionäre, die alleine oder zusammen mindestens |
(c) shareholders who hold, alone or together, shares representing at least | |
(Absätze 3 und 4 unverändert) | (Paragraphs 3 and 4 unchanged) | |
Artikel 9 | Article 9 | |
(Absatz 1 unverändert) | (Paragraph 1 unchanged) | |
2 Die Einberufung zur Generalversammlung erfolgt durch einmalige Bekanntmachung |
2 Notice of the General Meeting of Shareholders shall be given by way of a single announcement | |
3 Mindestens 20 Kalendertage vor der ordentlichen Generalversammlung sind der Geschäftsbericht, der Vergütungsbericht und, die Revisionsberichte sowie sofern
erforderlich der Bericht über die nichtfinanziellen Belange nach Artikel 964c OR den Aktionären elektronisch zugänglich zu machen |
3 The annual report, the compensation report | |
4 Die Einberufung muss Datum, Beginn, Art und Ort der Versammlung, die Verhandlungsgegenstände |
4 The notice shall specify the date, beginning, mode and venue of the meeting, the items on the agenda as well as the proposals of the Board of Directors and the
shareholder(s) |
Artikel 10 | Article 10 | |
1 Aktionäre, die alleine oder zusammen |
1 Shareholders who, alone or together, | |
(Übrige Absätze unverändert) | (Remaining paragraphs unchanged) | |
Artikel 13 | Article 13 | |
1 Die Generalversammlung beschliesst und wählt mit der |
1 The General Meeting of Shareholders shall pass its resolutions and decide its elections by the | |
2 Ein Beschluss der Generalversammlung, der mindestens zwei Drittel der vertretenen Stimmen und die |
2 Two thirds of the votes represented and the | |
(Ziffern 1 bis 3 unverändert) | (Items 1 to 3 unchanged) | |
4. |
4. |
5. die Kapitalerhöhung aus Eigenkapital, gegen Sacheinlage oder |
5. an increase in share capital through the conversion of equity surplus, against contributions in kind or | |
(Ziffern 6 und 7 unverändert) | (Items 6 and 7 unchanged) | |
8. die Zusammenlegung von Aktien; | 8. the combination of shares; | |
9. den Wechsel der Währung des Aktienkapitals; | 9. the change of currency of the share capital; | |
10. die Dekotierung der Beteiligungspapiere der Gesellschaft; | 10. the delisting of the Companys equity securities; | |
(Bisherige Ziffern 8 bis 10 entsprechend neu nummeriert) | (Existing items 8 to 10 renumbered accordingly) | |
(i) Artikel 5 Absatz 26;
(ii) Artikel 12 Absatz 2;
(iii) Artikel 13 Absatz 2 Ziffern 3,
(iii) Artikel 14; und
(iv) Artikel 17. |
(i) Article 5 paragraphs 26;
(ii) Article 12 paragraph 2;
(iii) Article 13 paragraph 2 nos. 3,
(iv) Article 14; and
(iv) Article 17. | |
3 |
3 | |
Artikel 24 | Article 24 | |
1 Die Generalversammlung wählt die Revisionsstelle für eine Amtsdauer |
1 The General Meeting of Shareholders shall elect the Auditors for a term of office | |
(Übrige Absätze unverändert) | (Remaining paragraphs unchanged) |
Abschnitt 9
Publikationsorgan, Mitteilungen
|
Section 9
| |||||
Artikel 34 | Article 34 | |||||
Publikationsorgan, Mitteilungen |
(Absätze 1 und 2 unverändert) |
Means of Publication, Notifications |
(Paragraphs 1 and 2 unchanged) | |||
3
|
3 |
2.3 | Agenda Item 11.3: Board of Directors, Compensation of the Executive Committee, Mandates Outside the Company |
The Board of Directors proposes to amend articles 18, 19, 26, 27 and 29 of the Articles of Association as shown below:
Artikel 18 | Article 18 | |
(Absatz 1 unverändert) | (Paragraph 1 unchanged) | |
2 Sofern das vom Verwaltungsrat erlassene Organisationsreglement oder ein Beschluss des Verwaltungsrates unter Einhaltung des anwendbaren Präsenzquorums nichts Anderes
festlegt, ist zur Beschlussfähigkeit des Verwaltungsrates die Anwesenheit der Mehrheit seiner Mitglieder erforderlich. Kein Präsenzquorum ist erforderlich für die Anpassungs- und Feststellungsbeschlüsse des Verwaltungsrates im
Zusammenhang mit |
2 Unless the organizational regulations adopted by the Board of Directors or a resolution taken by the Board of Directors with the applicable attendance quorum provide otherwise,
the Board of Directors shall only have a quorum if the majority of the members of the Board of Directors is present. No attendance quorum shall be required for resolutions of the Board of Directors providing for the amendment and ascertainment of a
capital | |
(Absätze 3 bis 5 unverändert) | (Paragraphs 3 to 5 unchanged) | |
Artikel 19 | Article 19 | |
(Absatz 1 unverändert) | (Paragraph 1 unchanged) | |
2 Er hat folgende unübertragbare und unentziehbare Aufgaben: | 2 It shall have the following non-transferable and inalienable duties: | |
(Ziffern 1 bis 5 unverändert) | (Items 1 to 5 unchanged) | |
6. die Erstellung des Geschäftsberichtes und, des Vergütungsberichtes und gegebenenfalls des Berichts über nichtfinanzielle Belange nach Artikel 964c OR und anderer gesetzlich vorgeschriebener Berichte; | 6. the preparation of the annual report | |
(Ziffer 7 unverändert) | (Item 7 unchanged) | |
8. die Beschlussfassung über die |
8. the adoption of resolutions on the | |
(Ziffern 9 bis 11 und Absatz 3 unverändert) | (Items 9 to 11 and paragraph 3 unchanged) | |
Artikel 26 | Article 26 | |
Reicht der bereits von der Generalversammlung genehmigte maximale Gesamtbetrag der Vergütung nicht aus für die Vergütung einer oder mehrerer Personen, die nach dem Zeitpunkt der Genehmigung der Vergütung der
Geschäftsleitung für die massgebende Vergütungsperiode durch die Generalversammlung Mitglieder der Geschäftsleitung werden |
If the maximum aggregate amount of compensation already approved by the General Meeting of Shareholders is not sufficient to also cover the compensation of one or more persons who become members of |
ermächtigt, diesem oder diesen Mitgliedern während der bereits genehmigten Vergütungsperiode(n) einen Zusatzbetrag auszurichten. Der Zusatzbetrag darf je Vergütungsperiode und je Mitglied 100% des jeweils letzten genehmigten Gesamtbetrages der maximalen Vergütung der Geschäftsleitung nicht übersteigen. | member(s) a supplementary amount during the compensation period(s) already approved. The supplementary amount per each compensation period and per each member shall not exceed 100% of the aggregate amount of maximum compensation of the Executive Committee last approved. | |
Artikel 27 | Article 27 | |
(Absätze 1 bis 3 unverändert) | (Paragraphs 1 to 3 unchanged) | |
4 Die Vergütung kann in der Form von Geld, Aktien, Optionen oder anderen Aktien basierten Instrumenten oder Anteilen oder Sach- oder Dienstleistungen ausgerichtet werden; die
Vergütung an exekutive Mitglieder des Verwaltungsrates und Mitglieder der Geschäftsleitung kann zudem in der Form von Optionen, vergleichbaren Instrumenten oder Einheiten gewährt werden. Der Verwaltungsrat oder, soweit
an ihn delegiert, der Vergütungsausschuss legt Zuteilungsbedingungen, Vesting-Bedingungen, Ausübungsbedingungen und -fristen und/oder allfällige Sperrfristen und Verfallsbedingungen fest. Sie können insbesondere vorsehen, dass
aufgrund des Eintritts im Voraus bestimmter Ereignisse wie eines Kontrollwechsels oder der Beendigung eines Arbeits- oder Mandatsverhältnisses Vesting-Bedingungen, Ausübungsbedingungen und -fristen, Sperrfristen und Verfallsbedingungen
weiter gelten, verkürzt oder aufgehoben werden, Vergütungen unter Annahme der Erreichung der Zielwerte ausgerichtet werden oder Vergütungen verfallen. Die Gesellschaft kann die erforderlichen Aktien auf dem Markt erwerben, den eigenen
Aktien entnehmen oder unter Nutzung ihres bedingten |
4 Compensation may be paid in the form of cash, shares, options or other share-based instruments or units, or in the form of other types of benefits; for the executive members of
the Board of Directors and the members of the Executive Committee, compensation may in addition be granted in the form of options or comparable instruments or units. The Board of Directors or, to the extent delegated to it, the Compensation
Committee shall determine grant, vesting, exercise, restriction and/or forfeiture conditions and periods. In particular, they may provide for continuation, acceleration or removal of vesting, exercise, restriction and forfeiture conditions and
periods, for payment or grant of compensation based upon assumed target achievement, or for forfeiture, in each case in the event of pre-determined events such as a change-of-control or termination of an employment or mandate agreement. The Company may procure the required shares through purchases in the market, from treasury shares or by using conditional | |
(Absatz 5 unverändert) | (Paragraph 5 unchanged) | |
Artikel 29 | Article 29 | |
(Absätze 1 und 2 unverändert) | (Paragraphs 1 and 2 unchanged) | |
3 Die folgenden Mandate fallen nicht unter dies Beschränkungen gemäss Absatz 1 und 2 dieses Artikels 29: | 3 The following mandates shall not be subject to the limitations set forth in paragraphs 1 and 2 of this Article 29: | |
(Buchstaben (a) und (b) unverändert) | (Letters (a) and (b) unchanged) | |
(c) Mandate in Vereinen und Verbänden, |
(c) mandates in associations, |
und ähnlichen Organisationen. Kein Mitglied des Verwaltungsrates oder der Geschäftsleitung kann mehr als zehn (10) solche Mandate wahrnehmen. | organizations. No member of the Board of Directors or of the Executive Committee shall hold more than ten (10) such mandates. | |
(Absatz 4 unverändert) | (Paragraph 4 unchanged) |
2.4 | Agenda Item 11.4: Jurisdiction Clause |
The Board of Directors proposes to introduce a new article 35 to our Articles of Association as shown below:
Abschnitt 10 | Section 10 | |||||
Gerichtsstand | Place of Jurisdiction | |||||
Artikel 35 | Article 35 | |||||
Gerichtsstand | 1 Ausschliesslicher Gerichtsstand für sämtliche aus oder im Zusammenhang mit dem Gesellschaftsverhältnis entstehenden Streitigkeiten (einschliesslich Streitigkeiten zwischen einzelnen Aktionären und der Gesellschaft oder ihren Organen, zwischen der Gesellschaft und ihren Organen oder zwischen Organen) ist der Sitz der Gesellschaft. | Place of Jurisdiction | 1 The exclusive place of jurisdiction for any disputes arising under, out of or in connection with or related to the corporate relationship (including disputes between individual shareholders and the Company or its corporate bodies, between the Company and its corporate bodies or between the corporate bodies themselves) shall be at the registered office of the Company. | |||
2 Unbeschadet von Absatz 1 dieses Artikels 35 hiervor kann die Gesellschaft ihre Organe und Aktionäre auch an deren ordentlichen Gerichtsstand belangen. | 2 Notwithstanding paragraph 1 of this Article 35, the Company may also sue its corporate bodies and shareholders at their ordinary place of jurisdiction. |
Existing sections 10 to 12 and existing articles 35 to 37 of the Articles of Association shall be renumbered accordingly.
Exhibit 99.2
VectivBio Publishes Invitation to the Annual General Meeting
May 10, 2023
BASEL, Switzerland, May 10, 2023 (GLOBE NEWSWIRE) VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the invitation to the 2023 Annual General Meeting, which will be held on Thursday, June 1, 2023, at 3:00 p.m. CEST / 9:00 a.m. EDT at Memox (meeting room Small Space), Elisabethenstrasse 15, 4051 Basel, Switzerland.
Shareholders entered in the companys share register with the right to vote as of May 2, 2023, at 10:00 p.m. CEST / 4:00 p.m. EDT will be entitled to participate in the 2023 Annual General Meeting. Shareholders may also be represented at the 2023 Annual General Meeting by the independent proxy or their proxy, who does not need to be a shareholder, by completing and signing a proxy form. Such proxy form can be downloaded on the Computershare portal alongside the admission ticket. For further information on how to attend the 2023 Annual General Meeting, to exercise rights, to issue voting instructions to the independent proxy or to grant proxy, shareholders can access the invitation to the 2023 Annual General Meeting at www.edocumentview.com/VECT.
About VectivBio AG
VectivBio (Nasdaq: VECT) is a global clinical-stage biotechnology company focused on transforming the lives of patients with severe rare conditions. Our lead product candidate is apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including short bowel syndrome with intestinal failure (SBS-IF) and acute Graft-versus-Host Disease (aGVHD).
VectivBio is also advancing its modular, small molecule CoMET platform to address a broad range of previously undruggable Inherited Metabolic Diseases (IMDs). Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA), propionic acidemia (PA), and other organic acidemias.
Learn more at www.vectivbio.com, and follow us on LinkedIn and Twitter.
Forward Looking Statements:
Forward-looking statements are statements that are not historical facts. Words and phrases such as anticipated, forward, will, would, may, remain, potential, prepare, expected, believe, plan, near future, belief, guidance, and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements concerning the timing of the 2023 Annual General Meeting. Such statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond VectivBios control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. Such risks and uncertainties include, but are not limited to those risks and uncertainties identified in the Risk Factors section of VectivBios Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 19, 2023 and its other subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, VectivBio undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact:
Patrick Malloy
VectivBio SVP, Investor Relations and Strategic Communications
Patrick.Malloy@vectivbio.com